Drug intelligence / Profile preview

interferon alfa-2a + interleukin-2

Development stage
Unknown
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous
01

Overview

Interferon alfa-2a + interleukin-2 is a combination immunotherapy regimen that utilizes two cytokines to stimulate the immune system against cancer cells. Interferon alfa-2a enhances the immune response by increasing the activity of natural killer cells and macrophages, while interleukin-2 promotes the growth and activity of T cells. This combination has been studied extensively in clinical trials for metastatic renal cell carcinoma, melanoma, and other advanced cancers, with varying administration routes including intravenous and subcutaneous delivery.

Brand names
Roferon-A
Other names
IFN alpha + IL-2IFN-α-2a + IL-2sc-IFN-α-2a + sc-IL-2
02

Targets

IFNAR (Immune system modulation via type I interferon receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on interferon alfa-2a + interleukin-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alfa-2a + interleukin-2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call